HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matthew L Winder Selected Research

Apoptotic Protease-Activating Factor 1

1/2022MCL-1 is a clinically targetable vulnerability in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Matthew L Winder Research Topics

Disease

2Breast Neoplasms (Breast Cancer)
01/2022 - 01/2021
2Neoplasms (Cancer)
01/2022 - 01/2021
1Autoimmune Diseases (Autoimmune Disease)
01/2022
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2022
1Leukemia
01/2022
1Multiple Myeloma
01/2022
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2022
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2022
1Triple Negative Breast Neoplasms
01/2022

Drug/Important Bio-Agent (IBA)

1Epidermal Growth Factor (EGF)IBA
01/2022
1InterferonsIBA
01/2022
1Proteins (Proteins, Gene)FDA Link
01/2022
1Estrogen ReceptorsIBA
01/2022
1Interleukin-6 (Interleukin 6)IBA
01/2022
1Protein Tyrosine PhosphatasesIBA
01/2022
1Immunoconjugates (Immunoconjugate)IBA
01/2022
1UbiquitinIBA
01/2022
1Apoptotic Protease-Activating Factor 1IBA
01/2022
16-pyruvoyltetrahydropterin synthase (PTPS)IBA
01/2022
1snake venom protein C activatorIBA
01/2022
1Proteolysis Targeting ChimeraIBA
01/2022

Therapy/Procedure

2Therapeutics
01/2022 - 01/2021